Targeting pyroptosis for cancer immunotherapy: mechanistic insights and clinical perspectives DOI Creative Commons
Chen Huang, Jiayi Li, Ruiyan Wu

et al.

Molecular Cancer, Journal Year: 2025, Volume and Issue: 24(1)

Published: May 3, 2025

Pyroptosis is a distinct form of programmed cell death characterized by the rupture membrane and robust inflammatory responses. Increasing evidence suggests that pyroptosis significantly affects tumor microenvironment antitumor immunity releasing damage-associated molecular patterns (DAMPs) pro-inflammatory mediators, thereby establishing it as pivotal target in cancer immunotherapy. This review thoroughly explores mechanisms underlying pyroptosis, with particular focus on inflammasome activation gasdermin family proteins (GSDMs). It examines role pyroptotic reshaping immune (TIME) involving both cells, discusses recent advancements targeting pathways through therapeutic strategies such small molecule modulators, engineered nanocarriers, combinatory treatments checkpoint inhibitors. We also advances future directions to enhance immunotherapy inhibitors, adoptive therapy, vaccines. study suggested offers promising avenue amplify responses surmount resistance existing immunotherapies, potentially leading more efficacious treatments.

Language: Английский

Targeting immune checkpoints in hepatocellular carcinoma therapy: toward combination strategies with curative potential DOI Creative Commons
Jing Tong,

Yongci Tan,

Wenhao Ouyang

et al.

Experimental Hematology and Oncology, Journal Year: 2025, Volume and Issue: 14(1)

Published: May 2, 2025

Abstract Hepatocellular carcinoma (HCC) is a primary liver cancer characterized by poor immune cell infiltration and strongly immunosuppressive microenvironment. Traditional treatments have often yielded unsatisfactory outcomes due to the insidious onset of disease. Encouragingly, introduction checkpoint inhibitors (ICIs) has significantly transformed approach HCC treatment. Moreover, combining ICIs with other therapies or novel materials considered most promising opportunity in HCC, some these combinations already being evaluated large-scale clinical trials. Unfortunately, trials fail meet their endpoints, few successful ones also face challenges. This indicates that potential treatment remains underutilized, prompting reevaluation this therapy. Therefore, article provides review role checkpoints treatment, research progress combination application aiming open up avenues for development safer more efficient checkpoint-related strategies Graphical abstract

Language: Английский

Citations

0
Targeting pyroptosis for cancer immunotherapy: mechanistic insights and clinical perspectives DOI Creative Commons
Chen Huang, Jiayi Li, Ruiyan Wu

et al.

Molecular Cancer, Journal Year: 2025, Volume and Issue: 24(1)

Published: May 3, 2025

Pyroptosis is a distinct form of programmed cell death characterized by the rupture membrane and robust inflammatory responses. Increasing evidence suggests that pyroptosis significantly affects tumor microenvironment antitumor immunity releasing damage-associated molecular patterns (DAMPs) pro-inflammatory mediators, thereby establishing it as pivotal target in cancer immunotherapy. This review thoroughly explores mechanisms underlying pyroptosis, with particular focus on inflammasome activation gasdermin family proteins (GSDMs). It examines role pyroptotic reshaping immune (TIME) involving both cells, discusses recent advancements targeting pathways through therapeutic strategies such small molecule modulators, engineered nanocarriers, combinatory treatments checkpoint inhibitors. We also advances future directions to enhance immunotherapy inhibitors, adoptive therapy, vaccines. study suggested offers promising avenue amplify responses surmount resistance existing immunotherapies, potentially leading more efficacious treatments.

Language: Английский

Citations

0